drugset
Drugs / ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS
last change Dec 2021 re-read 3 minutes ago

ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS

Cell therapy

Developed for
COVID-19
Investigated by
Andalusian Network for Design and Translation of Advanced Therapies

Trials 1

today NCT04366323 · Ph 1/2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04366323 Apr 2020 → Dec 2021 COVID-19 Andalusian Network for Design and Translation of Advanced Therapies Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS ClinicalTrials.gov intervention name — accepted as the source's own label NCT04366323 ↗
Modality Cell therapy “adipose-tissue derived mesenchymal stem cells” NCT04366323 ↗
Route Intravenous “Intravenous Administration” NCT04366323 ↗